A

Dr. Chris Abell, Co-founder, Astex Technology; a Reader in Chemistry at Cambridge University.

Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board, Beyond Genomics; A recognized entrepreneur in the life sciences, Dr. Afeyan is President and CEO of the NewcoGen Group and a special partner at OneLiberty Ventures in Cambridge, Massachusetts. Before founding NewcoGen Group in 1999, Dr. Afeyan was senior vice president and chief business officer at PE Corp. (Now Applera Applied Biosystems NYSE: ABI). While at PE, Dr. Afeyan initiated and oversaw the creation of Celera Genomics (NYSE: CRA), a tracking stock subsidiary of PE Corp.. PerSeptive merged with PE Corporation in 1998 in a deal valued at $360 million. Dr. Afeyan earned his undergraduate degree in Chemical Engineering from McGill University in Montreal and his Ph.D. in Biochemical Engineering at MIT.

Gary Alianell, PhD, is COO, EraGen Biosciences. He received a PhD in molecular genetics from the University of South Carolina, an MS in biochemistry from the State University of New York, and a BS in biology from St John Fisher College. He has served in executive management positions with start-up companies such as Oxford GlycoSystems, Molecular Devices, Transgenomics, and, most recently, NucleoTech Corporation, where he was CEO & President. He currently serves on the advisory panel for several market newsletters and scientific organizations. Dr. Alianell has authored both scientific papers and business marketing articles. E-mail

Dr. Mor Amitai, CEO, Compugen. Mor Amitai has been with the company since 1994. Between 1991 and 1995 worked in speech recognition, using HMM long before they were used in bioinformatics, at Efrat Future Technologies Ltd., a subsidiary of Comverse Technologies. Between 1986 and 1991 he carried out algorithm and communications system development in the IDF, which he left as a captain. Has a B.Sc. in Mathematics and Physics, a M.Sc. and a Ph.D. in Mathematics, all from the Hebrew University.

N. Leigh Anderson, Ph D., CSO, LSBC. Dr. Anderson obtained his B.A. in Physics with honors from Yale and a Ph.D. in Molecular Biology from Cambridge University (England). Subsequently he co-founded the Molecular Anatomy Program at the Argonne National Laboratory (Chicago) where he developed 2-dimensional electrophoresis (2-DE) and molecular database technology. In 1985, Dr. Anderson co-founded what is now the Company's proteomics subsidiary (originally Large Scale Biology Corp., Rockville, MD).

Norman G. Anderson, Ph.D., Chief Scientist, Proteomics, LSBC. Dr. Anderson has a distinguished record as an inventor. His career includes senior positions at Oak Ridge and Argonne National Laboratories (ORNL and ANL), more than 300 scientific publications, and the receipt of more than 20 prestigious awards in recognition of his work in science and technology and his many commercially important inventions, including the zonal ultracentrifuge and the centrifugal fast analyzer. In 1984 ANL awarded him its career patent leader award for the largest number of patents issued to an employee. Dr. Anderson received his degrees at Duke University: a B.A. in Zoology, M.A. in Physiology and Ph.D. in Cell Physiology. He is an inventor in 28 patents.

Ron D. Appel, Ph.D. in Computer Sciences, Co-founder GeneBio, is director of the Molecular Imaging and Bioinformatics Laboratory at Geneva University Hospital. He is responsible for the development of the SWISS-2DPAGE reference map database, the Melanie software package for 2D PAGE analysis and is co-creator of the ExPASy proteome analysis web server.

Cheryl Arrowsmith, Ph.D., co-CSO, Integrative Proteomics. Cheryl Arrowsmith is a co-founder and co-CSO. Dr. Arrowsmith also remains a Professor at the University of Toronto and Senior Scientist at the Ontario Cancer Institute. She received her Ph.D. in Chemistry from the University of Toronto in 1987 and received her post-doctoral training at Stanford University. Dr. Arrowsmith is an expert in chemistry, nuclear magnetic resonance spectroscopy and protein structure. She has published over 50 peer-reviewed papers and is the recipient of many awards for her research, including a Premier's Research Excellence Award and a Medical Research Council of Canada Scientist Award.

B

Dr David Bailey CEO, De Novo Pharmaceuticals. David has 15 years of management experience in the pharmaceutical industry. An initial position as Senior Investigator at Smith-Kline in Philadelphia was followed by his appointment as Head of Molecular Sciences at Pfizer's Sandwich (UK) facility. During his 8 years at Pfizer, David assembled a 60-strong team of scientists to leverage the impact of genomics across Pfizer's R&D portfolio. Recognising the central importance of genomics to drug discovery, in 1997 David joined Incyte Pharmaceuticals (Palo Alto, CA) as Vice President to set up the world's first Pharmacogenomics research team and establish Incyte's European HQ in Cambridge, UK. As CEO and an Executive Director of De Novo, David has responsibility for the day-to-day running and commercial direction of the company. E-mail

Amos Bairoch, Ph.D. in Biochemistry, Co-founder GeneBio, is group leader at the Department of Medical Biochemistry of the University of Geneva. He is responsible for the development of the SWISS-PROT, PROSITE and ENZYME databases and is co-creator of the ExPASy proteome analysis web server.

Richard Benarous, Co-founder and scientific advisor, Hybrigenics. He is a specialist of the development of cDNA libraries. He has published several important articles in the application of the two-hybrid technology to HIV research and has identified new targets for potential new anti-viral drugs. He holds several patent applications in this area.

John Bergeron, Ph.D., CSO, Caprion Proteomics. John is currently the Chairman of the Department of Anatomy and Cell Biology at McGill University and a recognized world expert in proteomics and cell biology. John co-developed and was principal scientist for the research that forms the basis of Cell Mapping, and will assume the scientific and strategic leadership of CaprionÕs proteomic efforts. John earned a B.Sc. from McGill University and a Ph.D. in Biochemistry from Oxford University as a Rhodes Scholar.

James Bernstein, M.D., President and COO, InforMax. James Bernstein, M.D. is President and Chief Operating Officer of InforMax. He has been an InforMax Director since its inception and was previously Chief Operating Officer and Executive Vice President of Strategic Development. Dr. Bernstein is a founder and Director of Age Wave, L.L.C., a holding company that develops businesses driven by population aging. He is also Chairman of Age Wave Impact, Inc., a relationship marketing company focusing on the 50+ population. From 1989 until 1994, Dr. Bernstein was engaged in the development of a private company for the distribution of pharmaceuticals and over-the-counter medicines in the former Soviet Union. Dr. Bernstein is also a founder and former Chief Executive Officer of General Health, Inc., an information publishing company in the field of health risk assessment and management. Dr. Bernstein has served as a special consultant to the National Heart, Lung and Blood Institute of the National Institutes of Health with a focus on disease prevention, control and physician education. Prior to his tenure at NIH, he was a Deputy Director of the Georgetown University Health Policy Center. From 1972 until 1974, Dr. Bernstein headed the office of the Chairman of the Board of Supervisors of San Diego County, California. Dr. Bernstein received his M.D. in 1964 from Cornell University Medical College and his Bachelor's degree in 1960 from Harvard College.

G. Montegu Black, Chairman, SYN¥X. Mr. Black has served as Chairman of the Board since its inception. Mr. Black is a well-known Canadian businessman and investor. Mr. Black, along with his brother, took control of the Argus Group of companies in the late 1970's. He is a former Governor of The Toronto Stock Exchange and Trustee of The Toronto Hospital and is currently Chairman and President of Txibanguan Limited and a Director of the Toronto-Dominion Bank, Hollinger Inc., Argus Corporation and The Tanbridge Corporation.

Jonathan Blackburn, CSO, Sense Proteomic. A Royal Society Research Fellow and a Fellow of Fitzwilliam College, Cambridge. Dr BlackburnÕs academic research interests range from the synthesis of novel enzyme substrates and inhibitors, through enzymology and molecular biology, to the development of new display methodologies and the creation of novel proteins. He has extensive experience of collaboration with industry and has published much innovative research in leading scientific journals. Dr Blackburn received both a BA and a D.Phil from the University of Oxford.

Sir Tom Blundell FRS, Co-founder, Astex Technology; Head of the Biochemistry Department at Cambridge University.

Joshua Boger, Ph.D., Chairman & CEO, Vertex. Dr. Boger is Vertex's scientific founder and was Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories. He headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. In 10 years at Merck, he developed an international reputation as a leader in the applications of computer modeling to the chemistry of drug design. He applied these techniques to the design of compounds in a number of therapeutic areas, including aspartic protease inhibitors. Dr. Boger received a B.A. in Chemistry and Philosophy from Wesleyan University, and M.A. and Ph.D. degrees in Chemistry from Harvard University in the laboratories of Professor Jeremy Knowles. He did postdoctoral research in molecular recognition in the laboratories of Professor Jean-Marie Lehn in Strasbourg, France.

Larry Bottomley PhD, VP of Research, Protiveris. He is an analytical chemist with an expertise in biological applications of scanning probe microscopy and electrochemistry. He is on sabbatical from the Georgia Institute of Technology.

Lydie Bougueleret, Ph.D., Chief Bioinformatician, GeneProt. Lydie Bougueleret joined Geneprot in November 2000 as Chief Bioinformatician. She was previously head of the Department of Biology in silico at Genset (France) and responsible for the genomic data processing and analysis. Dr. Bougueleret started her professional activity at EMBL in Heidelberg Germany. Her career then led her to the Pasteur Institute in Paris, Genethon and Millennium (Boston). She holds a Ph.D in Sciences and has authored more than 30 publications and is an inventor on more than 20 patents.

Joan Brooks, Ph.D., VP, Proteome Unit, Incyte Genomics.

Douglas L. Brutlag, Ph.D., Chief Scientist, DoubleTwist. Dr. Brutlag joined DoubleTwist in June 1999. He continues to hold his full time positions at Stanford University School of Medicine as professor of biochemistry and medicine and director of the bioinformatics resource while acting as DoubleTwistÕs Chief Scientist. Dr. Brutlag has been a member of the Stanford University faculty since 1974. Prior to that, he was a research scientist at the Commonwealth Scientific and Industrial Research Organization in Canberra, Australia. An internationally known expert in computational biology, he was a co-founder of the International Society for Computational Biology and an organizer of the Second and Seventh International Conferences on Intelligent Systems for Molecular Biology. In addition, he worked with UNIDO to teach bioinformatics to scientists from 40 developing countries and he was the 1992 winner of the Computerworld-Smithsonian award in Science. Dr. BrutlagÕs industrial experience includes the co-founding of two companies, IntelliCorp and IntelliGenetics. He also serves on the scientific advisory board of Time Logic, Inc.. He received his Ph.D. in biochemistry from Stanford University.

Mr. Brian R. Bullard, VP and Chief Information Officer, AxCell. Most recently he was with Perkin-ElmerÕs life sciences division, PE Biosystems, where as Manager, Data Products, he was in charge of scientific and market evaluation of data in conjunction with Perkin-ElmerÕs bioinformatics software platforms. Previously, Mr. Bullard was Director of Bioinformatics, Development at Gene Logic in Maryland, responsible for the biotechnology firmÕs information technology. Mr. Bullard has sixteen years of IT experience and has held a number of other information technology positions with firms including Science and Technology Corporation, OptiMetrics, Inc., and The Physical Sciences Laboratory.

C

Jacques Camonis, Co-founder and scientific advisor, Hybrigenics. He is one of the world leaders in the development of two- and three-hybrid systems in yeast. He has published important articles in this field, and holds a key patent application on the Three-Hybrid ("Two+One Hybrid") technology.

John Carney, Chairman, Nonlinear Dynamics

Dr. John Mark Carter, Director of Chemistry, AxCell. He was previously employed by CYTOGEN as a Principal Research Scientist. Prior to this, he served as a Captain in the U.S. Army at the Walter Reed Army Institute of Research. He was a Principal Research Scientist in the Divisions of Biochemistry and Communicable Diseases & Immunology, and was Company Commander of a medical support unit during Operation Desert Storm. He is an Adjunct Associate Professor at the Rutgers University Department of Biology. He received his B.A. degree in biology from Washington University in St. Louis. Dr. Carter holds a Ph.D. in Biochemistry and Molecular Biology from the University of Florida.

John A. Chakel, VP, Bioanalytical Systems, LumiCyte. Dr. Chakel has 19 years of focused experience in biotechnology-related industry leading the development of state-of-the-art mass spectrometry technology and applications, for the characterization of complex biomolecules and biopharmaceuticals, especially in genomics and proteomics. Previously at Agilent/Hewlett-Packard Laboratories, Dr. Chakel developed time-of-flight mass spectrometry systems/applications for furthering research collaborations and technology development. He also helped to define Agilent's/Hewlett - Packard's present role in the life sciences. Prior to Agilent/HP, Dr. Chakel was instrumental in innovating MS applications in biotechnology at Genentech from 1982 to 1990 and was a co-founder of Genomyx. He later joined Charles Evans & Associates to develop organic/ biological applications of TOF-SIMS and MALDI TOF-MS. He has his BS Chemistry with high distinction/honors, University of Michigan; Ph.D., Analytical Chemistry, Michigan State University. Dr. Chakel is an active participant (Board of Directors, 1998-2000, American Society for Mass Spectrometry) and member of a number of peer and standard-setting professional organizations.

John Chiplin Ph.D., President and CEO, GeneFormatics. Dr. Chiplin, President, Chief Executive Officer, and co--founder of GeneFormatics, has worked for a number of early stage bio-infotech companies that went on to become successful, multinational, profitable companies, including Molecular Design Limited and Biosym Technologies, Inc. Immediately prior to co--founding GeneFormatics, Dr. Chiplin was Chief Executive Officer of Superscape plc, one of the world's leading virtual reality technology companies, quoted on the London Stock Exchange. Born in 1958, he holds a B.S. in pharmacy and a Ph.D. in biochemistry from the University of Nottingham, England. Professional affiliations include memberships in the Pharmaceutical Society, the Royal Society of Arts, and the Institute of Directors.

Calvin Y.H. Chow Founder and COO, Caliper. Mr. Chow was previously with Molecular Devices Corporation from 1985 to 1995, where he was Vice President of Engineering and Operations. In that role, he was responsible for all instrument and software development and company-wide manufacturing for a line of sophisticated microplate readers and biosensor-based instruments. Prior to Molecular Devices, Mr. Chow was Director of Engineering and Marketing at Wavetek from 1982 to 1985. There he was responsible for the identification and development of integrated communications test and measurement systems for the mobile communications market. Prior to Wavetek, Mr. Chow was with Hewlett Packard from 1977 to 1982 as a Research and Development Engineer, where he developed several RF and Microwave test and measurement systems. He received his B.S. in electrical engineering from Illinois Institute of Technology and his M.S. in electrical engineering from Stanford University. He is a co-inventor on several bioanalytical system patents.

Gustav Christensen, M.B.A., CEO, Phylos. Mr. Christensen joined Phylos in August 2000 as Chief Executive Officer. Most recently, Mr. Christensen was Chairman of Primedica and Co-Founder, Director, and consultant to Phytera. Prior to this, Mr. Christensen worked in various capacities including Chairman, Founding Director, investor, and consultant to several companies, e.g. Alpha-Beta Technology, Diatide, Insmed, Geltex, and several private companies. From 1988 to 1990, he served as Chief Executive Officer of ImmuLogic, and from 1983 to 1988 he served as Senior Vice President, Commercial Affairs at Genetics Institute. From 1976 to 1983, Mr. Christensen held a variety of management positions at Baxter International. He holds an MBA from Harvard Business School.

David Coffen, Ph.D. - CSO, Discovery Partners. From 1995 until joining us, he served as Senior Vice President of Chemistry at ArQule, Inc. Prior to joining ArQule, Dr. Coffen held the position of Vice President Molecular Sciences at Hoffman-La Roche Inc., a research-oriented healthcare group, where he served in numerous research and development positions during his 24-year career. Dr. Coffen received a B.S. in chemistry from the University of Toronto and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Charles Cohen, Ph.D., President and CEO, Cellzome and one of the founders. Dr. Cohen was a founder of Creative Biomolecules, Inc. and served as its President, CEO and Chairman from 1985-1995.

Lawrence K. Cohen, Ph.D., CEO, Zyomyx. Dr. Cohen joined Zyomyx in April 1999 and, prior to assuming his position as Chief Executive Officer in January 2001, served as Chief Operating Officer.Ê In this role, Dr. Cohen was responsible for all internal activities including research and development, business development, financing and operations.Ê Before joining Zyomyx, Dr. Cohen served from 1997 to 1998 as the Chief Operating Officer of Progenitor, Inc., where he was responsible for technology and business development.Ê Prior to joining Progenitor, Dr Cohen served from 1988 to 1997 as the Vice President of Research and Development of Somatix Therapy Corporation, a publicly traded gene therapy company.Ê At Somatix, he maintained a basic research effort and oversaw the growth of a six-person research group into a fully integrated R&D function of 80 people responsible for the production of biological materials for six FDA-monitored clinical trials.Ê Dr. Cohen received a Ph.D. in Microbiology from the University of Illinois and completed his post-doctoral work in Molecular Biology at the Dana-Farber Cancer Institute and the Department of Biochemistry at Harvard Medical School.Ê

John Couch, CEO, DoubleTwist. Mr. Couch joined the company in September, 1997, bringing 30 years of management experience in strategic planning, product development, and computer science to DoubleTwist. Prior to joining the company, he was an Executive-in-Residence for the Mayfield Fund. During his tenure he provided strategic planning, management, and technology counsel to high-tech companies. Before joining Mayfield, Mr. Couch served with Apple Computers where he held a series of positions from Director of New Products, to Vice President of Software and Publications, leading up to Vice President and General Manager of Personal Office Systems Division where he pioneered Apple's initial "GUI" computer. As one of Apple«s original five Vice Presidents John's tenure coincided with Apple«s growth from 7 million to 1 billion in sales. Initially recruited by Hewlett - Packard in 1972, Mr. Couch quickly rose to Section Manager in Hewlett - Packard's General Systems Division. Mr. Couch holds both a B.S. in Computer Science and a M.S. in Electrical Engineering and Computer Science from the University of California at Berkeley.

Professor Daan Crommelin, Managing Director, Glaucus Proteomics.Professor Daan Crommelin studied pharmacy in Groningen and graduated as a pharmacist in 1975. He obtained his Ph.D. at the University in Leiden in 1979 on a thesis entitled: 'In vitro release studies on drugs suspended in non-polar media'. In 1979 and 1980 he worked as a post-doctoral fellow with prof. W.I. Higuchi at the University of Michigan. In 1980 he was appointed faculty member at the Department of Pharmaceutics and he became full professor and head of the department in 1984. In the summer of 1992 he became Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS) and in 1993 deputy managing director of the Groningen Utrecht Institute for Drug Exploration (GUIDE). In 1993 he was appointed adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. From 1989 until 1995 he was scientific secretary of the International Pharmacy Federation (F.I.P.) and Secretary of the Board of Pharmaceutical Sciences of the F.I.P. In September 1995 he was one of the two founders of OctoPlus, B.V., a company focused on providing high tech pharmaceutical formulation know how. This company has grown steadily and employs 40 highly skilled employees. Presently he acts as CSO of OctoPlus BV. He published over 260 original articles, reviews and book chapters. He was Associate Editor of J. Drug Targeting, the European Editor of the J. Controlled Release (together with prof. Hennink) and Special Feature Editor of Pharmaceutical Research. At the present he is European Editor of Pharmaceutical Research. Crommelin is member of the editorial (advisory) board of : 1) Pharm. Research, 2) J. Controlled Release, 3) Pharmaceutical Technology International, 4) Int. J. Pharmaceutics, 5) Adv. Drug Delivery Reviews, 6) European J. Pharm. Sciences, 7) Pharmaceutical Development and Technology, 8) J. Pharm. Sci., 9) AAPSPharmSci and 10) AAPSPharmSciTech. He was (one of) the editor(s) of the series 'Topics in Pharmaceutical Sciences' (every two years) until 1993, of a theme issue of Advanced Drug Delivery Reviews, of the book 'From Clone to Clinic', the book 'Physical methods to characterize pharmaceutical proteins' and the book 'Pharmaceutical Biotechnology. An Introduction for Pharmacists and Pharmaceutical Scientists'. He is Fellow of the American Association of Pharmaceutical Scientists (A.A.P.S.). He was the winner of the Maurice-Marie Janot award in 1995. He received the International Award of the Belgian Society of Pharmaceutical Sciences in 1997. He is involved in organizing meetings in the field of biopharmaceutics, drug targeting and the development of biotechnological products all over the world.

D

Hugh D'Andrade, Chairman of the Board, Myriad Genetics. Former Vice Chairman of Schering-Plough Corp. Hugh A. D'Andrade has served as Chairman of the Board since February 2001. Mr. D'Andrade was formerly Vice Chairman and Chief Administrative Officer of Schering-Plough Corporation and was a member of the Board of Directors of Schering-Plough Corporation since 1984. Prior to joining Schering-Plough, Mr. D'Andrade was Senior Vice President of the pharmaceutical division of Ciba-Geigy Corporation (now Novartis). Mr. D'Andrade earned a law degree, cum laude, from Columbia University School of Law and holds a bachelor's degree in economics from Rutgers University. Ê

Nathaniel David, Ph.D., Co-founder and Director, Business Development, Syrrx. Dr. Nathaniel David was primarily responsible for assembling the company and currently serves as Syrrx's Director of Business Development. Dr. David received his A.B. in Biology and Biochemistry from Harvard College (1990) and his Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley (1998). As one of the earliest employees of Cell Genesys, Inc., Dr. David was one of the genetic engineers responsible for developing the Xenomouse, a transgenic animal now marketed by Abgenix, Inc. During his doctoral work, Dr. David developed novel methods for the production, purification, and crystallization of cell-surface receptors.

Joseph Davie, M.D., Ph.D., Chief Scientific Advisor, Beyond Genomics; Dr. Davie joins Beyond Genomics after holding positions as Senior Vice President, Department of Research at Biogen, Inc. and Corporate Senior Vice President, Science and Technology, at G.D. Searle & Co. Before entering the corporate world, Dr. Davie was Head of the Department of Microbiology and Immunology at Washington University School of Medicine, St. Louis, Missouri. Dr. Davie received his Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine.

Dr. Roger E. Davis, Director of Bioinformatics, AxCell. Prior to joining AxCell he was a Vice President at Science and Technology Corporation. Dr. Davis managed the Las Cruces, New Mexico office for STC and also served as a Program Manager and Senior Scientist during his 18 years with the company. He received his B.A. in Physics from Hastings College and his Ph.D. in Astronomy from New Mexico State University.

Professor William Dawson, Non-Executive Director, Proteome Sciences. Professor Dawson retired from Eli Lilly in August 1996 after 27 years' service, 14 as Research Director in the United Kingdom and latterly as Director of Technology Acquisition, Europe. He is a Fellow of the Royal Pharmaceutical Society and of the Royal Society of Chemistry.

Dr Philip Dean CSO, De Novo Pharmaceuticals. Philip has over 30 years of research experience in the University of Cambridge, much of that time being funded by the Wellcome Trust on the development of computational methods for bio-molecular interactions and drug design. A long association with Rh™ne-Poulenc focused his attention on the need for algorithms to help the pharmaceutical industry. He has published extensively and has 4 books on drug design methods. He received the Astra Prize in 1989. As CSO and an Executive Director of De Novo, Philip has responsibility for the scientific direction of the company. E-mail

Will Dracup, Managing Director / Technical Director, Nonlinear Dynamics, Chairman of the Board, Nonlinear USA Inc Will attended Manchester University where he received a degree in Economics. For two years after graduating, Will worked as a freelance developer, creating a software package to teach French using graphics and animation for the BT Firebird range and developing management information systems. After this he attended a CDI Programming Technology course and then went on to work for Densitron Computers Ltd. Here he was responsible for support and software development on various high-end imaging devices. In 1988, he returned to freelance work. His first contract was in Milan as senior programmer for System Designers plc, where he worked on next generation ATM machines and a project to re-write the X-400 communications for the Italian inter-bank network. His next contract was for Scantech Imaging, where he developed an image database for electron microscopy applications. In 1989, he spent 9 months with Joyce Loebl Ltd, where he held sole responsibility for the development of several Life Science Image Analysis Products including 3D limb modeling, 2D electrophoresis and whole body autoradiography. During this time, he was Secretary of the Mensa Artificial Intelligence Interest Group and a member of the Neural Computing Applications Forum Editorial Board. In September 1989, he founded Nonlinear Dynamics Ltd. He was solely responsible for the development of the first version of Phoretix 2D, and the first version of Phoretix 1D in 1993. Whilst Will retained responsibility for the subsequent versions of Phoretix 2D, he has now had to take a back seat on development because of the increasing demands on his time as Managing Director. E-mail

Robert Dunkle, President, CEO, Scimagix. With more than 20 years' experience in general management, business development and marketing strategy in bio- and cheminformatics markets, Dunkle previously served as president and CEO of National Center for Genome Resources. Before that, he was VP at MDL Information Systems Inc., managing its ISISª cheminformatics software platform prior to being acquired by Reed Elsevier.

Dr. Michael Dunn, Scientific Advisory Board, Proteome Sciences. Dr. Dunn is a Reader in Biochemistry, Division of Cardiothoracic Surgery Imperial College School of Medicine at NHLI, Heart Science Centre, Harefield Hospital. Dr. Dunn is President of the British Electrophoresis Society and is also the Scientific Advisor to the Board.

Professor Raymond Allen Dwek, Non-Executive Director, OGS. Has been a non-executive director since 1988 and was, as founding scientist, instrumental in our inception in 1988. He has been a member of the Scientific Advisory Board since 1997. A Fellow of the Royal Society, he is the director of the Glycobiology Institute and a Professor of Glycobiology at the University of Oxford. His other positions include Head of he Department of Biochemistry at the University of Oxford, Professorial Fellow of Exeter College, Fellow of the Royal Society of Chemistry and a Member of the European Molecular Biology Organisation. He is also a director of Penmarric Plc and Synergy Pharmaceuticals Inc and Chairman of he Board of Directors for Oxford University Consultancy Limited. He is the author of three books and is named as an inventor in a number of patents and patent applications.

E

Aled Edwards, Ph.D., Chairman, Office of the Chief Scientists, Integrative Proteomics.Aled Edwards ,is a cofounder and Chairman, Office of the Chief Scientists. Dr. Edwards also remains a Professor at the University of Toronto and Senior Scientist at the Ontario Cancer Institute. He received his Ph.D. from McGill University in 1988 and received his postdoctoral training at Stanford University. Dr. Edwards is an expert in protein purification, protein crystallography and molecular biology. He has published over 50 peer-reviewed papers and is the recipient of many awards for his research, including a Premier's Research Excellence Award and a Medical Research Council of Canada Scientist award.

David Eisenberg, co-founder, Protein Pathways. David Eisenberg is Professor of Molecular Biology, Chemistry, and Biological Chemistry at UCLA. He is author and coauthor of some 200 publications on the structures, functions, and interactions of proteins, as well as two books. Since 1993 he has served as Director, UCLA-DOE Lab of Structural Biology and Molecular Medicine, where he is responsible for administering a broad range of research programs in structural biology, genetics, and molecular medicine. Since about 1980, Eisenberg has worked on the computational biology of proteins. His interests focus on the interpretation of genome sequences in terms of structure and function. He holds two patents, and has several patents pending in this area. Eisenberg has been honored by the Stein and Moore Award of the Protein Society, the Pierce Award of the Immunotoxin Society, the Repligen Award of the American Chemical Society, and the National Award of the Biophysical Society. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences.

Robert L. Erwin, Chairman of the Board, co-founder and CEO, LSBC, and has served as a director and officer since 1987. Mr. Erwin is the former chairman of the State of California Breast Cancer Research Council and currently serves on the University of California President's Engineering Advisory Council. He is Chairman of the Supervisory Board of Icon Genetics AG. As a co-founder of Sungene Technologies Corp., Mr. Erwin served as Vice President of Research and Product Development from 1981 through 1986. Mr. Erwin received his M.S. degree in Genetics from Louisiana State University.

Markus Ewert, PhD, President and Chief Executive Officer, Xerion. E-mail

F

Simchon Faigler - Executive VP and CTO, Compugen. Simchon Faigler served eight years in the IDF's Talpiot unit, during the first three of which he completed a BA at the Hebrew University in Physics and Mathematics. For the following five years he was seconded to Tadiran's communications division where he defined and developed rapid hardware for smart communications systems.

Gregory G. Freitag, J.D., CEO and a director, HTS Biosystems. Mr. Freitag is a director of Quantech Ltd. (Minneapolis, Minnesota), where he served as chief operating officer from June of 1997 through March of 2001 and as chief financial officer and secretary from December of 1995 through March of 2001. From 1987 until joining Quantech, Mr. Freitag was a partner with the law firm of Fredrikson & Byron P.A. (Minneapolis, Minnesota), where his practice focused on corporate, securities, and merger and acquisition law. Mr. Freitag has served on securities advisory committees to the Minnesota Commissioner of Commerce, serves on the University of Minnesota Biological Sciences Technology Transfer Advisory Committee, and is an invited speaker in the areas of biotechnology and corporate development. He was included in the Minnesota Business Guide to Law and Leading Attorneys and received the City Business "40 under 40" award, recognizing him as one of the Twin Cities' next generation of business and community leaders.

Jacquelyn Fetrow, Ph.D. CSO, GeneFormatics. Dr. Fetrow co-founded GeneFormatics in 1998 and is currently Chief Scientific Officer and a member of the Board of Directors. Dr. Fetrow is co-inventor of one of GeneFormatics' key technologies, the Fuzzy Functional Form™, developed while she was on the faculty at The Scripps Research Institute. Her research there focused on protein function prediction. From 1990 to 1998, she was a member of the faculty in the Department of Biological Sciences at the University at Albany in New York. Her research there, funded by the NIH, the NSF, and the American Chemical Society, focused on understanding the relationship between protein structure and function. During her tenure at Albany, she received several awards for Excellence in Teaching. Dr. Fetrow earned a Ph.D. in biochemistry from Pennsylvania State University in 1986. Her postdoctoral work, funded by an NIH fellowship, focused on studying protein and peptide structure and was carried out in the laboratories of Dr. Fred Sherman at the University of Rochester and of Dr. Peter Kim at the Whitehead Institute at MIT. She is co-author on over 50 peer-reviewed journal articles and other scientific publications in relating to computational analysis of protein structure, NMR and other spectroscopic studies of cytochrome c, and studies of protein structure and function relationships. She has served on many scientific review panels, is currently on the editorial board of the journal, Proteins: Structure, Function, Genetics, and is a member of numerous professional societies.

John L. Flavin, Executive VP and COO, MediChem; CEO, ThermoGen and Emerald BioStructures.

Michael T. Flavin, Ph.D., Chairman of the Board of Directors, President and CEO, MediChem.

Hugo Fluhler, Ph.D., CFO and Co-founder, GeneData.

G

Jim Garrels, Ph.D., Senior VP, Proteome Unit, Incyte Genomics.

Dr. Elias Georges, President and CEO, Aurelium BioPharma Inc.

Walter Gilbert, Ph.D., Director Vice Chairman of the Board, Myriad Genetics, Carl M. Loeb University Professor, Harvard University Walter Gilbert, Ph.D., Vice Chairman of the Board of Directors, joined the Company as a founding scientist in March 1992. Dr. Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology. He was a founder of Biogen, Inc. and its Chairman of the Board and Chief Executive Officer from 1981 to 1985. He presently holds the Carl M. Loeb University Professorship at Harvard University.

Frank Gleeson, President and CEO, MDS Proteomics. Frank Gleeson brings 25 years of business leadership to his post as president and chief executive officer at MDS Proteomics. Prior to MDS Proteomics, Gleeson was senior vice president and partner of MDS Capital Corporation, where he was responsible for building numerous early stage biotechnology and biomedical businesses. He was also the portfolio manager for the Canadian Medical Discoveries Fund Inc., a $250 million investment fund focused on early stage health care and life sciences companies. Previously, Frank had a lengthy management career with ICI plc, both in Canada and internationally, as an operating executive with global responsibility working extensively with emerging technologies in a wide range of fields. He spent one year as the executive vice president of the International Centre of Agri-Food Science and Technology, where he completed several multi-million dollar financings in this sector. Gleeson received his Bachelors and Masters of Business Administration from York University in Ontario. He has served on the boards of numerous companies and organizations, including TSE listed companies GenSci Inc., GlycoDesign Inc., and Nexia Inc. as well as private companies such as Geminx Inc. and TerraGen Inc.

Larry Gold, Ph.D., director, HTS Biosystems. He has been chief executive officer and chairman of the board of SomaLogic, Inc., since its inception in 1999. SomaLogic is a proteomics company using the aptamer technologies developed at NeXstar Pharmaceuticals, Inc., which merged with Gilead Sciences in 1999. In 1991, he founded NeXagen, which became NeXstar. Dr. Gold was also a founder of Synergen, a company involved in optimizing gene expression in bacteria and creating thermostable commercial enzymes. For 21 years, Dr. Gold taught at the University of Colorado, Boulder, and was chair of molecular, cellular and developmental biology. Dr. Gold has authored, or co-authored, more than 120 United States patents and has consulted with more than 25 biotech and pharmaceutical companies in the area of gene expression in bacteria.

Steven A. Gold, Ph.D. Director of Bioinformatics, CuraGen.

James Golden, Ph.D. Director of Bioinformatics, CuraGen.

Linda S. Grais, M.D., J.D., Executive VP and Founder, Structural GenomiX. Dr. Grais is a physician and attorney with broad experience working with emerging companies in the life sciences. From 1993 to 1997, she worked in the Life Sciences Group at Wilson Sonsini Goodrich & Rosati representing companies in venture capital financings, public offerings, technology licensing and corporate partnering transactions. Prior to this, Dr. Grais was an Assistant Professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais has served as a consultant to the Institute of Medicine and the Council on Foreign Relations. She received her law degree from Stanford Law School, medical degree from Yale Medical School and undergraduate degree Magna Cum Laude and Phi Beta Kappa from Yale University.

Jack Greenblatt, Ph.D., cofounder and co-CSO, Integrative Proteomics. Dr. Greenblatt remains an Ann and Max Tannenbaum Professor of Molecular Medicine at the University of Toronto. He received his Ph.D. from Harvard University in 1973 and received his postdoctoral training at the University of Geneva and the Pasteur Institute. He is an expert in gene expression, protein purification, protein-protein interaction and mass spectrometry. He has published 100 peer-reviewed papers. Dr. Greenblatt is the recipient of a Medical Research Council of Canada Distinguished Scientist Award, a Fellow of the Royal Society of Canada and an International Research Scholar of the Howard Hughes Medical Institute.

H

Arnold Hagler, Ph. D. - Served as CEO and Chairman of Structural Proteomics since May 2000, Discovery Partners. In 1997, Dr. Hagler founded ScienceMedia.com, an educational software company. From 1984 to June 1997, Dr. Hagler was with Biosym Technologies, Inc., a computational software company which he founded. Since 1998 Dr. Hagler has been Adjunct Professor of Chemistry at the University of Massachusetts at Amherst. He received a B.S. in chemistry and a Ph.D. in physical chemistry from Cornell University.

Timothy J Haines BSc MBA, CEO, Astex Technology; brings over 18 years senior management experience in healthcare. Prior to joining Astex, Mr Haines was President and CEO Intervascular Inc and President of the Patient Monitoring Division, Datascope Corporation (1993-2000). He previously held Chief Executive positions with companies in the US and Europe. Mr Haines received a BSc from Exeter University, UK, and a Master of Business Administration from INSEAD, France.

Jari HŠkkinen Ph.D., CTO, BioBridge Computing; He has a Ph.D. in Theoretical Physics, Lund University. Non academic work includes image processing, automatized quality check of grain and development of bioinformatics products for leading pharmaceutical companies.

Dr William Hamilton, Director Research & Development, Proteom. Bill has many years experience managing commercial research in the biotechnology industry. He set up and managed Agricultural Genetics Company Ltd. (AGC)'s in-house research facilities, which eventually formed the foundation of Axis Genetics Ltd. and was a member of a successful three-man management buyout team that acquired Axis in 1995. Axis specialised in the research, development and production of recombinant vaccines from plants. Bill held the position of Research Director and was a member of the Axis Board. Bill has also acted as a biotechnology consultant to the EU and UK Government bodies as well as several companies. E-mail

Dr. William Hancock, VP and general manager of proteomics, Thermo Finnigan. Dr. Hancock came to Thermo Finnigan from HP/Agilent Laboratories, where he was principal scientist focusing on developments in bioscience. Before joining HP, Dr. Hancock was director of analytical chemistry at Genentech, Inc. He earned his Ph.D. and D.Sc. in chemistry from the University of Adelaide in Australia. Dr. Hancock also serves as President of the California Separation Science Society (CASSS).

R. Steven Harris, Non-Executive Director, Proteome Sciences. Steve Harris is a Member of the Royal Pharmaceutical Society. He has 30 years' experience in the pharmaceutical industry including ICI, Merck Sharpe & Dohme, Eli Lilly, Boots, Reckitt and Colman, Gensia and Medeva. He acts as a Non-Executive Director of PolyMASC plc, SkyePharma plc and a number of other biotechnology companies.

Tim Harris, Ph.D., President and CEO, Structural GenomiX. Timothy Harris, Ph.D is President and Chief Executive Officer of Structural GenomiX. He also serves on the Board of Dendreon Corporation. From 1993 to 1999, Dr. Harris was Senior Vice President of Research and Development for Sequana Therapeutics, Inc. which became Axys Pharmaceuticals, Inc. in 1998. At Sequana/Axys, he expanded the research group from ten to over 200 people and secured four corporate deals. From 1989 to 1993, he was Director of Biotechnology at Glaxo Group Research in the United Kingdom, where he held responsibility for global high throughput screening. From 1981 until 1989, Dr. Harris was a senior molecular biologist at Celltech Ltd., a biotechnology company in the UK, cloning various genes coding for therapeutic proteins. Dr. Harris received a Ph.D. and M.S. in General Virology and a B.Sc. in Biochemistry from the University of Birmingham in England.

Dr Jonathan Heal, Director Informatics Applications, Proteom. Jon, with a Ph.D. in Biochemistry from Imperial College, London has extensive experience not only in organic chemistry, protein structure and folding but also in the informatics of sequence database analysis. Jon has developed the novel algorithms and approaches which together form the software suite for the analysis of databases to identify and optimize complementary sequences. This informatics approach has developed the technology platform that is the basis of Proteom. E-mail

John Hefti, M.D., Ph.D., Founder & Chief Technical Officer, Signature Bioscience. Dr. Hefti is the Founder of SBS, and architect behind the MCS technology. Prior to his present position, he has held appointments at Stanford University Medical Center, the University of California at Berkeley, Lawrence Livermore National Laboratory, and Columbia University. His expertise spans numerous areas of applied and medical physics with research topics ranging from condensed matter theory and quantum electronics to protein biophysics. Dr. Hefti holds an M.D. from Stanford University, a Ph.D. in physics from the University of California at Berkeley, and an A.B. in mathematics from Columbia University.

Stefan W. Henning, PhD, Director of Functional Biology, Xerion. E-mail

Dr. Juan J. Herrero, Director of Screening, AxCell. Prior to his current position he was a Senior Research Scientist at CYTOGEN. Before joining CYTOGEN, he worked at Cadus Pharmaceutical Company as a scientist in the high-throughput screening group. He holds a Masters Degree in Molecular Biology from the University of Basel, Switzerland. Dr. Herrero did graduate work at Hoffman-La Roche, Inc. and received his Ph.D. in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey.

Robert Hillman, Ph.D., Co-founder and CEO, Activx. Prior to Activx, Dr. Hillman founded Accumetrics in 1995. He served as President and CEO until July 1997, and then served as Executive Vice President. Accumetrics successfully took a concept for monitoring of platelet function to an FDA-approved product in four years. The company also had significant contracts with large pharmaceutical companies as part of their drug development process. From 1987 to 1995, Dr. Hillman worked in senior management positions in product and business development at Gensia Pharmaceuticals, Inc. Dr. Hillman was a Vice President of Gensia Pharmaceuticals and directed the GenESA System Program, a closed loop drug delivery system for the diagnosis of coronary artery disease which was approved for marketing in the European Community and the U.S. Dr. Hillman was also involved in managing key liasions with European Partners and was the founder of Automedics, later spun off by Gensia. Prior to that, Dr. Hillman was one of the founding employees at Biotrack, Inc. (later sold to Boehringer Mannheim), and was the principle inventor of two major products at that company. He also held research and development positions at Liposome Technology, Syva Company and Alza Corporation. Dr. Hillman received his B.S. in Biomedical Engineering from Stanford University, a S.M. in Chemical Engineering from the Massachusetts Institute of Technology, and a Ph.D. in Chemical Engineering from the Swiss Federal Institute of Technology.

Dr Sean Hird, COO and Company Secretary, Inpharmatica. Sean joined Inpharmatica in November 1998. Sean is responsible for the Company's day-to-day administration with special responsibility for legal and patenting matters. Prior to joining Inpharmatica, Sean was Head of Legal Affairs at the Centre for Applied Microbiology and Research, Porton Down, and before that General Counsel and Company Secretary at CRC Technology (the Cancer Research Campaign's technology transfer arm). Sean qualified as a solicitor with City law firm, Clifford Chance and went on to specialise in commercial law before joining CRC Technology. Sean has a PhD in Molecular Biology from the University of Cambridge and a Diploma in Intellectual Property Law from the University of Bristol.

Denis F. Hochstrasser, M.D., Co-founder GeneBio, Professor of Medicine is head of the Central Clinical Chemistry Laboratory at Geneva University Hospital. He is an authority on 2D PAGE technology and a pioneer in its application in the medical field. Scientific Advisory Board, Proteome Sciences. Professor Hochstrasser is the Head of Clinical Chemistry at the University of Geneva; committee member of the International Congress of Electrophoresis Societies; President of the Swiss Electrophoresis Society and a member of the Scientific Swiss Council. Author of over two hundred scientific publications, he is a recognised authority in protein markers.

Christian Hodal H.D., Co-founder and CFO, ACE Biosciences; H.D. Master of Business Studies; E-mail

Jean-Paul Hofmann, Ph.D., VP, Software Development, Proteomics, LSBC. Dr. Hofmann is a plant geneticist by training, having earned a B.S. in Biology, M.S. in Biochemistry and Genetics and Ph.D. in Plant Genetics from the University of Orsay, Paris. He has extensive experience in using 2-DE in agronomic research and in designing analytical software for 1- and 2-D applications. He has held senior scientific positions in industry and research institutes, in the U.S., France and the Ivory Coast.

Ian Humphery-Smith Ph.D., Managing Director and COO, Glaucus Proteomics. Ian Humphery-Smith received his Ph.D. in Parasitology from the University of Queensland in 1984. He followed this with post-doctoral studies in virology (exotic arboviruses in the Coral Sea) and bacteriology in France (principally, biocontrol of malaria vectors) before returning to Australia in 1992 to take a position as Course Coordinator in Medical Microbiology & Immunology at the University of Sydney. During this posting, he also became Executive Director of Australia's second largest DNA sequencing facility (prior to the advent of ABI 3700's) and Director of the Centre for Proteome Research and Gene-Product Mapping. The latter became the world's first center for 'proteome' research through significant funding obtained from Glaxo Wellcome, UK. He also played an active role in the establishment of the Australian Proteome Analysis Facility. His research work in proteomics has been conducted over the last ten years and in July 1995 gave rise to the term 'proteome' first being introduced to the scientific literature. Recently, he has published the most complete view of the protein content of a living organism, Mycoplasma genitalium. In August 1999, he took up a founding Chair in Pharmaceutical Proteomics at the Universiteit Utrecht in The Netherlands and is currently the Chief Operating Officer of Glaucus Proteomics B.V., a company aspiring to produce antibody arrays for the differential analysis of the Human Proteome in health and disease. Prof. Humphery-Smith is also currently a prime mover in efforts to have the Human Proteome Project become a formally-ratified international initiative to follow-on from the Human Genome project.

T. William Hutchens, CEO, LumiCyte. Dr. Hutchens has 20 years of experience leading efforts in protein biology and pioneering the development of enabling technologies for protein mapping and discovery. The patented SELDI process and protein BioChip array technology were invented by Dr. Hutchens while on the faculty at Baylor College of Medicine, where he held tenured professorships in the departments of Cell Biology, Pediatrics, and Obstetrics and Gynecology. He has been responsible for the successful financing, development and commercialization of SELDI BioChip products in both the pharmaceutical and biotechnology industries. He founded Molecular Analytical Systems in 1993 and IllumeSys Pacific in 1996. Dr. Hutchens served as the Executive Vice President and Chief Technical Officer of Ciphergen Biosystems after its merger with IllumeSys Pacific in 1997. He founded LumiCyte in 1999 to provide the pharmaceutical and healthcare industries with integrated BioChip-based proteomics and bioinformatics products to enable early detection of disease and response to therapy. Dr. Hutchens holds an A.B. degree in Biology from UCLA and a Ph.D. from USC for his work on drug-protein molecular recognition events regulating gene expression.

I

Leodevico L. Ilag, PhD, CSO, Xerion. E-mail

J

George Jackowski, Ph.D., Vice Chairman, CSO, SYN¥X. Dr. Jackowski is the founder of SYN¥X. Previously, Dr. Jackowski was the co-founder of Spectral Diagnostics Inc. and the inventor of the Spectral Cardiac PanelTM. He was President and Chief Technical Officer of Spectral from December 1990 to January 1997. Dr. Jackowski is the recipient of the 1996 MEDEC Award for Medical Achievement for his invention of the Cardiac STATusTM CK-MB/Myoglobin Panel Test, which aids in the early diagnosis and rule out of myocardial infarction in patients with chest pain. Dr. Jackowski is the author of 42 scientific publications, 54 abstracts and 10 patents filed in the U.S. and internationally. Dr. Jackowski holds academic positions at the University of Toronto and the Toronto Hospital. Dr. Jackowski has a Ph.D. in clinical biochemistry from the University of Toronto and is a trained Cardiovascular Biochemist.

Dr. Ian Jardine, President, Thermo Finnigan.ÊÊDr. Jardine is recognized as an industry leader in opening the door for bioanalysis using mass spectrometry. He saw early on that unraveling the complexity of biological systems would require data-rich analytical tools such as liquid chromatography and mass spectrometry. Before joining Thermo Finnigan in 1989, Dr. Jardine served at the Mayo Clinic.

Harren Jhoti Ph.D., Co-founder and CSO, Astex Technology; previously led the Structural Biology and Bioinformatics groups at Glaxo Wellcome (1991-1999), applying protein structure analysis to drug discovery. In addition, he was also involved in structure-based drug design projects aimed at a variety of therapeutic targets. Dr Jhoti also played an active role in one of the BBSRC's research funding committees. Dr Jhoti received his PhD in Protein Crystallography from Birkbeck College, University of London, UK.

K

Hidong Kim, Ph.D., VP of Operations Ð Emerald BioStructures, MediChem.

Angus King Ph.D, Co-founder and CSO, ACE Biosciences; Ph.D Molecular and Cellular Biology. E-mail

Daniel L. Kisner, M.D., President and CEO, Caliper. Dr. Kisner joined Caliper from Isis Pharmaceuticals where he was President and Chief Operating Officer. He had previously been responsible for business development, product development, and manufacturing as Executive Vice President. Prior to joining Isis, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories where he led a team of 650 scientists, physicians and support personnel. His responsibilities included the preclinical and clinical development of all Abbott Laboratories' ethical pharmaceuticals. Dr. Kisner has also held the position of Vice President of Clinical Research and Development for International Studies for SmithKline Beckman Corporation and has a tenured position in the Division of Oncology at The University of Texas, San Antonio School of Medicine. Dr. Kisner is certified by the American Board of Internal Medicine and certified in Medical Oncology. He is the author of more than 50 scientific papers and 40 abstracts in clinical journals and textbooks. Dr. Kisner received his M.D. from Georgetown University in 1972.

Nikolai Kley, Ph.D. VP Functional Genomics, Head of Research, Boston GPC Biotech. Dr. Nikolai Kley, who joined GPC in 1999, previously held positions as Director and VP Functional Genomics at Genome Therapeutics Corporation (Waltham/Boston, USA). While there, Dr. Kley was instrumental in establishing numerous functional genomics technology platforms and research programs, including a collaborative oncology program with Princeton University. Prior to 1997, Dr. Kley held posts as Senior Scientist and Group Leader/Principal Scientist within Oncology Drug Discovery at Bristol Myers Squibb Pharmaceutical Research Institute. He also spent several years at Harvard Medical School and the Massachusetts General Hospital (Boston, USA), working in the fields of cancer genetics and biology. Dr. Kley retains his adjunct faculty position as Research Professor at the Department of Molecular Biology at Princeton University.

Michael R. Knapp, Ph.D. Founder and VP of Corporate Development, Caliper. Prior to co-founding Caliper, Dr. Knapp was President, Scientific Director, a Director and a Scientific Advisory Board Member at Molecular Tool, Inc., a company he co-founded in 1988. Under his direction, the company developed a proprietary DNA typing system with the demonstrated capability of performing up to 2.5 million genotype determinations per year. This system is rapidly becoming a standard for parentage determination in both veterinary and human applications. Additionally, Dr. Knapp authored a proposal in 1994 that was one of only eleven nationwide to receive a $2 million technology development grant from the Department of Commerce's Advanced Technology Program in their first "Tools for DNA Diagnostics" focus competition. From 1981 to 1986, he was scientific director of Genetica, S.A. in Joinville-le-Pont, France, a genetic engineering affiliate of French chemical giant Rh™ne Poulenc. Dr. Knapp was a Senior Scientist on the staff of Columbia University's Center for Neurobiology and Behavior from 1986 to 1988, using the tools of molecular genetics to study the complex processes of learning and behavior in model biological systems. Dr. Knapp received his B.S. from Trinity College (Hartford) in biology in 1973. He received his Ph.D. in Medical Microbiology from Stanford University, specializing in recombinant DNA technology in 1981.

James R. Knight, Ph.D. Director of Bioinformatics, CuraGen.

Mark Knuth, Ph.D., Director, Protein Chemistry, Syrrx. Dr. Mark Knuth is Director of Protein Chemistry at Syrrx. Prior to joining Syrrx, Dr. Knuth worked at Promega Corporation overseeing projects involving protein purification, characterization, assay development, and applied enzyme evolution. He directed development of nine commercial products Ê and assisted in the development of ten other products, one of which received an R&D 100 award. Dr. Knuth also worked for seven years as a bioanalytical and peptide/protein chemist at The Upjohn Company where he improved clinical assays, conducted exploratory research in peptide structure/function and preparative and analytical HPLC of proteins. He also developed a proprietary process for large-scale refolding of bovine somatotropin, which scaled economically to 50-kilogram batches of purified protein. In addition to his ten publications and five issued patents (two pending), Dr. Knuth has been an invited presenter at scientific conferences on protein purification, co-authored a book on protein purification and characterization, and taught at Cold Spring Harbor Laboratory. Dr. Knuth received a B.A. in Chemistry from Kalamazoo College (1979). He received a Ph.D. in Cell and Molecular Biology from the University of Wisconsin (1991), working at the McArdle Laboratory on the identification and purification of eukaryotic transcription factors under Richard Burgess.

Dr. Andreas Kopke, CEO, Chairman of the Board of Directors, WITA Proteomics.

Caroline A. Kovac, VP Life Sciences Solutions, IBM.

John W. Kozarich, Ph.D., President and CSO, Activx. Dr. Kozarich joins ActivX with over 20 years experience in academic and pharmaceutical research. Most recently, he was Vice President at Merck Research Laboratories, where he was responsible for programs including antimicrobial drug discovery, enzymology, 5a-reductase biology, lipid biochemistry, nuclear receptors, ion channels and structural biology. He has been involved in a number of Merck drug programs, including Propecia, Type-1 5a-reductase inhibitor, and MRSA carbapenams. He also has had primary responsibility for a number of Merck collaborations with biotechnology companies, such as Aurora Biosciences, Cubist and KaroBio. In addition, he has played a major role in Merck's acquisition of SIBIA and in the development of its new Boston Research Center. Previously, Dr. Kozarich held faculty positions at the University of Maryland, College Park, and Yale University School of Medicine. He also served as Vice President, Research and Development at Alkermes, a biotechnology company that develops products based on sophisticated drug delivery technologies. Dr. Kozarich is internationally known for his work on enzyme mechanisms and on the chemistry of DNA cleaving antitumor drugs. He was an American Cancer Society Faculty Research Awardee and in 1988 received the Pfizer Award in Enzyme Chemistry of the American Chemical Society for his unique and broad research contributions. He has also served on numerous government and academic committees. Dr. Kozarich has authored over 125 primary scientific publications and holds three patents

Roland Z Kozlowski, CEO, Sense Proteomic. Dr Kozlowski has an established track record both in research, scientific management and collaboration with industry. Instrumental in Oxford MolecularÕs business development and collaborative solutions division where he was the founding scientist and Director of its leading drug design initiative on ion channels in collaboration with Yamanouchi Pharmaceutical Co Ltd. Dr Kozlowski received a BSc degree from Bath and a PhD from Cambridge. Dr Kozlowski, formerly from Oxford, holds a faculty position at the University of Bristol.

Michael Louis Kranda, CEO, OGS. Joined as Chief Executive Officer in 1996 after 11 years with Immunex Corporation,where he held the position of President and Chief Operating Officer from 1990 to 1996. Prior to joining Immunex Corporation, he was the Chief of Staff in the office of the King County Prosecuting Attorney in Seattle, Washington. He is currently a board member of the Washington Research Foundation.

Brent L. Kreider, Ph.D., VP, Biological Research, Phylos. Dr. Kreider joined Phylos in July 1998 from Human Genome Sciences, Inc. (HGS) where he created and directed the Department of High-Throughput Biological Screening. Prior to this position at HGS, he also served as Associate Director, Department of Cell Biology and as Staff Scientist. Dr. KreiderÕs academic experience focused on the mechanisms of hematopoietic progenitor cell differentiation and how these controls may be altered during oncogenic transformation and leukemia. Dr. Kreider received his Ph.D. in molecular biology from the University of Pennsylvania. He conducted his postdoctoral fellowship on acute myeloid leukemia in the laboratory of Dr. James Ihle at St. Jude ChildrenÕs Research Hospital.

L

Mike Lack, COO and Executive VP, Incyte Genomics.

Eric S. Lander, Ph.D., Advisor, NewcoGen, Professor of Biology at the Massachusetts Institute of Technology and Director of the Whitehead Institute/MIT Center for Genome Research Dr. Lander's research interests are human genetics, mouse genetics, population genetics, and computational and mathematical methods in biology. He and his research group have developed genomic maps of the human, mouse and rat genomes in connection with the Human Genome Project and techniques for the genetic analyses of complex, multigenic traits. He has applied these techniques to the understanding of cancer, diabetes, hypertension, renal failure and dwarfism. Dr. Lander earned his A.B. in Mathematics from Princeton and his D. Phil. in Mathematics from Oxford University.

Ashley Lawton, Ph.D., M.B.A., President, Phylos. Dr. Lawton, previously Vice President, Operations at Genzyme Corporation, joined Phylos in August 1997. Prior to his tenure with Genzyme, he served as Executive Vice President and General Manager of Repligen Corporation and held senior management positions with Celltech Biologics and Eli Lilly & Co. Ltd. He has an established track record in managing biotechnology operations, negotiating deals involving technology licensing and contract services, and developing protein biopharmaceuticals. Dr. Lawton received his Ph.D. in biochemistry from Southampton University, U.K. He is also a graduate of the Executive M.B.A. Program of Boston University.

Martin D. Leach, Ph.D. Director of Bioinformatics, CuraGen.

Pierre Legrain, Co-founder and VP Science and Technology, Hybrigenics. Pierre Legrain is Vice-President Science & Technology at Hybrigenics.Dr Legrain is a leader in the development of whole genome analysis for protein-protein interactions using the Two-Hybrid in yeast system. He has published key articles in this field and holds important patent applications.

Stephen E. Lincoln, Executive VP, Product Development and CSO, InforMax. Mr. Lincoln, who joined InforMax in December 2000, was previously the senior vice president of Life Science Informatics for the company with responsibility for corporate product development. Before joining InforMax, Mr. Lincoln was the vice president of Bioinformatics Research and Development at Incyte Genomics, where he was responsible for directing scientific and product strategies for the company's genomic databases. Prior to Incyte Genomics, he was a scientist with Dr. Eric Lander at the Whitehead Institute at MIT and was a founding member of the MIT/Whitehead Genome Center. In addition, Mr. Lincoln directed bioinformatics efforts supporting SNP genotyping at Molecular Tool, Inc. (now Orchid BioSciences, Inc.). He was also a visiting scientist at the Cold Spring Harbor Laboratory, and an R&D engineer for Hewlett-Packard's Medical Product Group.

CŽdric Loiret-Bernal, M.D. CEO, GeneProt. CŽdric Loiret-Bernal, M.D. joined GeneProt in April 2000 as Chief Executive Officer and Director. Previously, Dr. CŽdric Loiret-Bernal was a Director and Senior Investment Analyst at Brinson Partners, Inc. His experience also includes responsibilities in Corporate Strategy at Abbott Laboratories from February 1995 to December 1997, in Marketing and Project Management at Haemonetics Corp. from 1992 to 1994, and Marketing at SynthŽlabo Biomedical from 1988 to 1990. Dr. Loiret-Bernal holds a MD degree from the University of Bordeaux and an MBA in finance and international business from the JL Kellogg Graduate School of Management at Northwestern University.

M

Edward T. Maggio, Ph.D., Chairman, CEO and President, Structural Bioinformatics. E-mail

Steve Mallam, Project Leader, Proteomics, Nonlinear Dynamics E-mail

Matthias Mann, Ph.D., Chief Proteomics Officer and Founder, MDS Proteomics. Many of the mass spectrometry-based techniques now in use in the field of proteomics were developed in Dr. Mann's laboratories in Germany and Denmark. Dr. Mann and his collaborators first developed and successfully applied extremely sensitive mass spectrometry-based proteomic analysis to study protein interactions and identify protein components in multi-protein complexes. Dr. Mann is a Professor in the Department of Molecular Biology,University of Southern Denmark in Odense, Denmark. He has also served as Group Leader at the European Molecular Biology Laboratory. Dr. Mann received his diploma thesis in mathematics and physics at the Georg August University, Gšttingen and the Max Plank Institut, Gottingen. He obtained his Ph.D. from Yale University where he was one of the developers of electrospray mass spectrometry in the group of J.B. Fenn. www.pil.sdu.dk

Professor Keith Mansford, Non-Executive Director and Chairman, Scientific Advisory Board,, Proteome Sciences. Professor Mansford was the Head of Research and Development at SmithKline Beecham PLC. He is a Professor of Biochemistry at the University of Buckingham and his consultancy practice, Mansford Associates, advises a range of international biotechnology and pharmaceutical companies.

Muzammil M. Mansuri, Ph.D. Executive VP & COO Boston GPC Biotech. Dr. Muzammil Mansuri was appointed EVP and COO, Boston, following GPC's acquisition of Mitotix in March 2000. Dr. Mansuri had been with Mitotix since 1994, most recently holding the post of Executive Vice President, Research. Prior to joining Mitotix, Dr. Mansuri spent nearly ten years at Bristol-Myers Squibb Company in various research positions, culminating in Director, Central Chemistry. Dr. Mansuri received his Ph.D. in Organic Chemistry from University College, London.

Vincent T. Marchesi, M.D., Ph.D., Co-Founder, Cognia: Dr. Marchesi heads the Boyer Center for Molecular Medicine at Yale School of Medicine where he is also Professor of Pathology and Cell Biology. Dr. Marchesi is a member of the National Academy of Sciences and the Institute of Medicine, and is currently the Editor-in-Chief of the FASEB Journal. He co-founded Molecular Diagnostics, Inc., and has served on the Board of Directors of the American Cyanamid Company.

Edward Marcotte, co-founder, Protein Pathways. Edward Marcotte is an assistant professor in the department of Chemistry and Biochemistry at the University of Texas at Austin. Prior to this he was an Alexander Hollaender Distinguished Postdoctoral Fellow conducting research with Professor Eisenberg at the UCLA-DOE Lab of Structural Biology and Molecular Medicine. Marcotte received his B.S. degree in microbiology and his Ph.D in biochemistry from the University of Texas. He has been author and coauthor of more than 15 scientific articles spanning experimental biochemistry to bioinformatics. In addition to the Hollaender Distinguished Postdoctoral Fellowship, Marcotte received the University of Texas Outstanding Dissertation Award, the Linus Pauling Prize of the American Crystallography Association, the Schuhardt Award in Microbiology, and was appointed the Robert E. Eakin Centennial Fellow and a National Science Foundation Graduate Fellow. Marcotte is co-inventor of Protein Pathways' technologies and is currently applying them to the first large-scale predictions of protein function. Ê

Donagh McCarthy, BE, MBA, President and CEO, Protiveris. Most recently, Mr. McCarthy was president of two startup businesses, RMS Lifeline and RMS Disease Management in Baxter Healthcare Corporation. Prior to that he held various other management positions including President of the North American Renal Division and General Manager Renal, Japan. Mr. McCarthy also serves on the Board of Resmed, a NYSE-listed company.

Mark McDade, CEO, Signature Bioscience. Before joining Signature Mr. McDade was President and Chief Operating Officer of Corixa Corporation. He was a co-founder of Corixa, serving as Executive Vice President and Chief Operating Officer since the company's inception, and as President and COO since March 1999. Prior to co-founding Corixa, Mr. McDade served as the Chief Operating Officer of Boehringer Mannheim Therapeutics, the pharmaceutical division of Corange Ltd. His prior experience includes various management positions with Sandoz Ltd. Mr. McDade also serves on the board of directors of Corixa Corporation and Valentis, Inc.

Ian McDonald, Ph.D., VP, Drug Discovery, Structural Bioinformatics. E-mail

David R. McGee, Ph.D., Chief Operating Officer, co-founder, LSBC, and has been an officer since 1987. Prior to joining LSBC, Dr. McGee was Vice President of Operations at Sungene Technologies Corporation from 1983 to 1987. Dr. McGee received his Ph.D. in Zoology and Genetics from Louisiana State University and served as a faculty instructor of zoology and genetics at Louisiana State University.

Sean McNicholas, MSc., Director, President and CEO, SYN¥X. Mr. McNicholas joined SYN¥X in January 2001. Prior to this Mr. McNicholas was Corporate Vice President of Pharmacia International's Endocrine Care Division headquartered in Peapack, New Jersey. Prior to this he was with Eli Lilly Canada as Vice President of Sales, Marketing and Government Affairs as well as various other positions. Mr. McNicholas holds a BSc. from Swansea University and a MSc. from the University of Alberta.

Duncan McRee, Ph.D., Director, Structure Determination, Syrrx. Dr. Duncan McRee is Director of Structure Determination at Syrrx. Dr. McRee comes to Syrrx from The Scripps Research Institute where he was Professor of Molecular Biology working to solve protein structures using X-ray crystallography. He has contributed 55 entries Ê to the Protein Data Bank, including the structure for the first microsomal P450 for which he received the Klaus Ruckpaul award for distinguished accomplishments in the field of P450 biology. In addition to his X-ray crystallographic work, Dr. McRee is known for his development of methods in protein structure determination, including development of the crystallographic software package, XtalView. He has consulted for BioSym, Molecular Simulations, Molecular Structure Corporation, and Molecular Images, and is the author of Academic Press' best-selling book, Practical Protein Crystallography (now in its second edition). Dr. McRee received his B.S. in Biochemistry (1979) from University of California, Davis and his Ph.D. in Biochemistry (1985) from Duke University, where he worked under Dave and Jane Richardson. As a Helen Hay Whitney Fellow, he did his post-doctoral work with Drs. Tainer and Getzoff at The Scripps Research Institute. Upon completion of his post-doctoral fellowship in 1989, Dr. McRee became Assistant Professor at The Scripps Research Institute. Dr. McRee has published over 50 scientific publications in major journals, including Nature and Science, and has presented at numerous national and international scientific conferences.

Sebastian Meier-Ewert, Ph.D. Senior VP & Head of Research, GPC Biotech. Dr. Sebastian Meier-Ewert, as a co-founder of GPC Biotech AG, serves the company as Senior Vice President and Head of Research. Previously, Dr. Meier-Ewert established and led a team working on gene expression analyses and bioinformatics at the Max Planck Institute for Molecular Genetics in Berlin. Dr. Meier-Ewert studied Biochemistry at University College, London. He completed his post-graduate training at the Imperial Cancer Research Fund in London, and received his Ph.D. from the University of London.

Peter D. Meldrum, Director President and CEO, Myriad Genetics. Peter D. Meldrum has been a Director of the Company since its inception in May 1991 and has been President and Chief Executive Officer of the Company since November 1991. Prior to joining the Company he was President and Chief Executive Officer of Founders Fund, Inc., a venture capital group specializing in the biotechnology industry. He received an M.B.A. degree from the University of Utah in 1974 and a B.S. degree in Chemical Engineering from the University of Utah in 1970.

John Mendlein, Chairman and CEO, Integrative Proteomics. An executive with more than fifteen years experience in the biotechnology industry, Dr. Mendlein most recently served as Chief Knowledge Officer, General Counsel and Senior Vice President, Intellectual Property of Aurora Biosciences Corporation (NASDAQ: ABSC). He was appointed to the Aurora Biosciences Board in November 2000. Prior to joining Aurora in 1996, Dr. Mendlein worked with the firm of Cooley Godward in Silicon Valley, focusing on biotechnology transactions, intellectual property and litigation. He was a Doctoral Trainee at Smith, Kline and French Pharmaceuticals, in the Department of Molecular Genetics, received his Ph.D. from the University of California, Los Angeles for his work on the biochemistry and biophysics of membrane proteins, particularly the pharmaceutical target, the H+/K+ ATPase, and his J.D. from the University of California, Hastings College of Law.

Bob Merold, Senior VP, Proteome Unit, Incyte Genomics.

Nagesh Mhatre, Chairman, Scimagix, former corporate vice president and division president of Becton Dickinson Immunocytometry Systems.

Michael Milburn, Ph.D., VP, Structural Biology, Structural GenomiX. Dr. Milburn directs high throughput X-ray crystallography across prokaryotic and eukaryotic genomes. He has 10 years of pharmaceutical experience in structure based drug discovery. Most recently, Dr. Milburn was department head of Structural Chemistry at Glaxo SmithKline. At GSK, he led the structure-based X-ray crystallography and computational chemistry groups, and focused efforts to exploit structural information for drug discovery in the hormone/steroid receptor family. Dr. Milburn began his work in the steroid/hormone receptor field in 1994 as a visiting scientist from Glaxo at Harvard Univeristy with Stephen Harrison. He was also responsible for coordinating the informatic needs of the research organization in developing and implementing computational tools. Dr. Milburn has authored over 50 publications in structural biology. He recieved his Ph.D. from Prof. Sung-Hou Kim's laboratory at UC Berkeley and his B.S. in Chemistry at the University of Michigan.

Mike Moran, Ph.D., Senior Vice-President, Discovery Research, MDS Proteomics. Mike Moran brings over twenty years of biotechnology research experience to his position of senior vice president of research of MDS Proteomics. Prior to joining MDS Proteomics, Moran was the founding vice president and chief scientific officer for MDS Ocata, Inc, a privately held, integrated biotechnology partner of MDS Proteomics. While there, he was responsible for leading proteomic research efforts to advance the company in its goal to identify and characterize protein-protein interactions as a source of novel drug targets. Concurrently, he was a visiting professor at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital and a tenured professor at the University of Toronto Faculty of Medicine, lecturing on molecular and medical genetics. His responsibilities at MDS Proteomics include the integration of advanced proteomics, drug discovery and supercomputing efforts towards the discovery and validation of new drug targets and therapeutic compounds. Since 1995, Moran has presented and lectured at over 50 international conferences, college and hospital engagements. He has published some 40 articles in international science journals and magazines, and these works have been cited over 3000 times in other publications. He has consulted and collaborated extensively with various biotech and Pharmaceutical partners, and served as member, chair and scientific officer for various national medical research granting agency study sections. Moran earned a Bachelor of Science in Biochemistry, and a PhD in Biochemistry from the National Cancer InstituteÕs Laboratory at the University of Western Ontario. He has held career Scientist awards from both the National Cancer Institute, and Medical Research Council of Canada.

Ejvind M¿rtz Ph.D, Co-founder and CEO, ACE Biosciences; Ph.D. Protein Chemistry. E-mail

N

Jocelyn H. Ng, PhD, Director of Protein Biochemistry, Xerion. E-mail

Steffen Nock, Ph.D., Senior Director of Biochemistry & Founder, Zyomyx. Dr. Nock co-founded Zyomyx in 1998. Prior to joining Zyomyx Dr. Nock's research focus was on structure-function analysis of nucleotide binding proteins. From 1996 to 1998, Dr. Nock was awarded a fellowship to carry out research in the Department of Biochemistry at Stanford University, where his work focused on molecular motors and cytokinesis in lower eukaryotes. At Stanford, Dr. Nock also collaborated with Dr. Wagner toward the development of new immobilization protocols involving new affinity tags for site-specific attachment. Prior to his work at Stanford, Dr. Nock carried out research in protein kinetics and the discovery of signaling pathways at the Max-Planck Institute of Molecular Physiology. He received a Diploma in Biochemistry and a Ph.D. in Biochemistry, both from the University of Bayreuth, Germany.

O

N. Stephen Ober, MD, MBA, President of Beyond Genomics; Dr. Ober comes to Beyond Genomics from Synergy Health Care, Inc., a company that he founded and where he served as President and CEO from 1995 to 2000. Dr. Ober was instrumental in establishing Synergy as a leading informatics company in the health care industry. Synergy is now a division of Quintiles Transnational, the largest provider of outsourced drug development, commercialization and health care informatics to the global pharmaceutical industry. Dr. Ober received his MBA from the Harvard Business School and his M.D. from Boston University School of Medicine.

Dr John Overington, Director of Drug Discovery, Inpharmatica. Following a first class degree in Chemistry John studied for a PhD with Sir Tom Blundell FRS, performing research on comparative protein modelling, drug design and sequence-structure relationships. This was followed with a postdoctoral fellowship with the Imperial Cancer Research Fund. In 1992, John joined Pfizer, initially as a molecular modeller, with a focus on the application of protein structure data applied to drug design. Prior to joining Inpharmatica, John was manager of the Molecular Informatics, Structure and Design department at Pfizer, covering Chemoinformatics, Structural Biology, Target Analysis and Molecular Modelling.

P

J. Wallace Parce, Ph.D. Founder and VP of Research, Caliper. Prior to joining Caliper, Dr. Parce spent 12 years with Molecular Devices Corporation as a Founder, Consultant, Director of Research and Vice President of Research. In his various capacities at MDC, he participated as an inventor on a number of patents including that for the company's key biosensor technology. He was also principal investigator on a $14 million DARPA contract aimed at putting a "human on a chip" for biowarfare detection and high throughput drug discovery based on functional receptor bioassays. Dr. Parce received his B.A. in Chemistry from Western Maryland College in 1972 and his Ph.D. in Biochemistry from Wake Forest University in 1976. During his Post Doctoral Fellowship in Chemistry at Stanford University under the direction of Prof. Harden McConnell he worked on several projects in humoral and cellular immunology. In 1980, he joined the Department of Biochemistry at Wake Forest University as an Assistant Professor continuing work on physical chemical and spectroscopic approaches to problems in immunology. In 1982, he became an Associate in the Department of Microbiology and Immunology and in 1984, an Associate Professor of Biochemistry.

Professor Raj Bhikhu Parekh, CSO, OGS. Was our founding Research Director and has been an executive director since 1992. He is internationally recognised in the fields of glycobiology, carbohydrate engineering and proteomics. He holds a DPhil from the University of Oxford, is author of numerous publications and is named as an inventor in a number of patents and patent applications.

Christopher Pearce, Managing Director, Proteome Sciences. Christopher Pearce was previously a Director of Smith New Court Securities plc and has extensive experience in company research, marketing and corporate finance. He has been involved with the Group since 1988 and has been responsible for the formulation and implementation of the Group's corporate strategy, particularly the development of the Group's collaborative and licensing agreements and intellectual property.

John Peeters, MSc, PhD, Chairman and Founder, Protiveris. Dr. Peeters is a leading expert in the field of biosensors and he is the co-editor of several books on biomarkers. He is the inventor of Protiveris' Protein Chip technology and the founder of Protiveris, Inc.

Matteo Pellegrini, President, Protein Pathways. Matteo Pellegrini received his bachelors degree summa cum laude at Columbia University, and his PhD. at Stanford University in Physics. Subsequently he became a postdoctoral fellow at the Molecular Biology Institute working with Professors Yeates and Eisenberg. He is an expert in computational biology, having published 18 articles on subjects ranging from molecular dynamics to bioinformatics. He received the Paul Boyer Postdoctoral Award, the Columbia Physics Department Alfred Moritz Michaelis Award, the Sloan Foundation/Department of Energy Postdoctoral fellowship in Computational biology and is a member of Phi Beta Kappa. Pellegrini is co-inventor of Protein Pathways' technologies and is acting president of the company. In his research capacity, he is currently focusing on computational methods for protein networks analysis.

Othmar Pfannes, Ph.D., CEO and Co-founder, GeneData.

Enrico Picozza, co-founder, COO,VP business development and a director, HTS Biosystems. Mr. Picozza spent 15 years with Applied Biosystems (AB), Inc., most recently in business development for the proteomics business unit, which involved coordinating efforts with Celera Inc. In 1985, he was the first to join what was then Perkin Elmer's new venture into biotechnology. This new venture was responsible for what became, and still is, the very successful PCR business. At AB, Mr. Picozza worked at various roles and spearheaded several programs in marketing, product development, technology assessment and acquisition. Mr. Picozza serves on the scientific advisory board for Quantech Ltd. He is the holder of eight patents, the author of several papers, an invited international speaker and the recipient of the "AB Outstanding Performance Award" for his contributions to AB's success. He earned his masters in molecular and cell biology from the University of Connecticut.

Riccardo Pigliucci - Chairman, President and CEO, Discovery Partners. Prior to joining Discovery Partners, he served as Chief Executive Officer of Life Sciences International PLC, a supplier of scientific equipment from 1996 to 1997. Prior to that, he held numerous management positions during his career at Perkin-Elmer Corporation, including President and Chief Operating Officer. Mr. Pigliucci is also a director of Epoch Biosciences, Inc., Biosphere Medical and Dionex Corporation, a trustee of The Worcester Foundation for Biomedical Research and a member of the Advisory Board of Chemical & Engineering News.

Michael Pisano, Ph.D. VP, Proteomics Research and Development, Genomic Solutions. Michael Pisano, Ph.D.: BS in Biology from the University of Dayton, 1984. Ph.D. in Biochemistry (Dr. Linda Dokas), 1989 from the Medical College of Ohio, Toledo, OH. Postdoc in Department of Neurochemistry at Medical College of PA and U of Penn, Philadelphia, PA, 1989-92. Scientist, Wyeth-Ayerst Pharmaceuticals, Dept of Biotechnology 1992-96. Section Manager Protein Biochemistry, Dept. of Gene Medicine, Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA, 1996-97. Department Manager, Proteomics and Protein Production, Dept of Biotechnology, Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA. Head, Protein Sciences, Dept. of Biotechnology Aventis Pharmaceuticals, Bridgewater, NJ, 1999-2000. Joined Genomic Solutions in May, 2000.

George Poste, D.V.M., Ph.D., Chairman, Structural GenomiX. From 1992 to 1999, Dr. Poste was President, R&D and Chief Science and Technology Officer at SmithKline Beecham and a member of the Board of Directors. During his twenty year tenure in the pharmaceutical industry he has been associated with 29 successful drug and vaccine registrations in the USA and internationally. Dr. Poste was educated in England and received a degree in Veterinary Medicine in 1966 and a Ph.D. In virology in 1969 from the University of Bristol. He was awarded the rank of Commander of the British Empire by Queen Elizabeth II in 1999. He has published over 300 scientific papers and book chapters and serves on the editorial boards of several journals. He is a Research Professor at the Universities of Pennsylvania and Texas in the USA and the William Pitt Fellow at the University of Cambridge in the UK

Dr. Michal Preminger - VP Proteomic Business, Compugen. Dr. Preminger joined Compugen in 1998 from Lucent Technologies, where she had served in as Director of Marketing and Business Development. Prior to that, she had served in a senior marketing management position at the LANNET division of Madge Networks (NASDAQ: MADGF), an international provider of data communications solutions, which was acquired by Lucent Technologies (NASDAQ: LU). Dr. Preminger holds a Ph.D. in Biological Sciences from the Weizmann Institute of Science, Department of Membrane Research and Biophysics, and an MBA from INSEAD. She holds a Bachelor of Medicine from the Hadassah Medical School, Hebrew University in Jerusalem, and M.Sc., Biological Sciences, from the Weizmann Institute of Science.

James Prudent, PhD, is CSO, EraGen Biosciences. Dr. Prudent has earned a BS from the University of Wisconsin-Madison and a PhD from the University of California at Berkeley in Chemistry. He has extensive knowledge in the areas of genetic research, genetic diagnostics as well as DNA and protein chemistries. He comes to EraGen from Third Wave Technologies where he co-invented the Invader Technology as well as Third Wave's structural DNA based patents. Dr. Prudent has authored numerous publications and is joint holder of five issued and several additional applied for patents. E-mail

Q

R

G Kirk Raab, Non-executive Chairman, OGS. G Kirk Raab Has been non-executive Chairman since 1995. Before this, he held positions as President and Chief Executive Officer of Genentech Inc and President and Chief Operating Officer of Abbott Laboratories.He is also non-executive Chairman of Accumetrics Inc and Connetics Corporation. In addition he is a non-executive director of Applied Imaging Corporation, Medgenics Inc, Velos Inc and Bridge Medical Inc. He was the founding chairman of he California Healthcare Institute and was the inaugural chairman of he Biotechnology Industry Organization. He is also a director of The National Foundation for Science and Technology Medals.

Kal Ramnarayan, Ph.D., VP and CSO, Structural Bioinformatics. E-mail

Fred Regnier, Ph.D., Co-founder and CTO, Beyond Genomics; A co-founder of Beyond Genomics and PerSeptive Biosystems, Dr. Regnier is a Professor of Chemistry at Purdue University. He is the author of over 200 publications and 15 patents on various aspects of chemistry and biochemistry, particularly separation techniques and their application to proteins. Dr. Regnier's current research focuses on proteomics and micro fabricated analytical systems. He completed his Ph.D. at Oklahoma State University and did post-doctoral work at the University of Chicago and Harvard University.

Marc Reymond, Assoc. Prof. MD, Chief Medical Officer, Europroteome. E-mail

William E. Rich, Ph.D., President and CEO, Ciphergen. William E. Rich, Ph.D. joined us in September 1994, as our President and Chief Executive Officer and as a director. Prior to joining us, Dr. Rich was Senior Vice President of Sepracor, Inc. from 1991 to 1994, and President of BioSepra, which was spun off by Sepracor. Prior to joining Sepracor, he was Senior Vice President of Dionex Corporation and from 1975 to 1990, he had responsibility for both the Marketing and Sales and Research and Development departments at various times during his tenure there. Dr. Rich received a B.S. in Chemistry from Carson Newman College and a Ph.D. in Chemistry from the University of North Carolina, Chapel Hill and conducted post-doctoral research in biochemistry at Duke University. E-mail

Dr Gareth Roberts, CEO, Proteom. Gareth's career has evolved from postdoctoral research in the field of neuropsychiatric disorders with the Medical Research Council, to building and leading a 10 strong team within Imperial College School of Medicine and as a Group Director of a discovery department in SmithKline Beecham Pharmaceuticals. He has also previously been instrumental in founding a successful genomics company (Genostic Pharma Limited) with venture capital funding from the Prelude Trust. E-mail

Dr. John D. Rodwell, President and CTO, AxCell. He joined Cytogen in September 1981. He served as Director, Chemical Research, then as Vice President, Discovery Research from 1984 to 1989, as Vice President, Research and Development from 1989 to July 1996, and as Senior Vice President and Chief Scientific Officer from July 1996 through June 1999, at which time he assumed full time duties as Acting President and Chief Technical Officer of AxCell. From 1980 to 1981, Dr. Rodwell was a Research Assistant Professor and, from 1976 to 1980, he was a postdoctoral fellow, both in the Department of Microbiology at the University of Pennsylvania School of Medicine, where he currently is an Adjunct Associate Professor in the Department of Microbiology. He holds a B.A. in Chemistry from the University of Massachusetts, an M.S. in Organic Chemistry from Lowell Technological Institute and a Ph.D. in Biochemistry from the University of California at Los Angeles.

Thorsteinn Ršgnvaldsson Ph.D., Co-founder, BioBridge Computing; He has a Ph.D. in Theoretical Physics, Lund University. Post-doc Dept. of Computer Science and Engineering, Oregon Graduate Institute, Portland, Oregon, USA. Part time post as Associate Professor at Halmstad University.

Prof. Keith Rose, Ph.D. CSO, GeneProt. Dr. Rose pioneered the techniques of protein quantitation by stable isotope dilution mass spectrometry, and of identification of carboxy-terminal peptides by oxygen labeling. In addition to his long-time interest in mass spectrometry, Dr. Rose is a synthetic chemist and the inventor of polyoxime artificial proteins, which are showing great promise as vaccines and as targeting agents, and have been tested clinically. He ran the recent small clinical trial of the malaria vaccine he produced himself in Geneva: further work is being supported in part by the US National Institutes of Health (NIH). Most recently, he invented a novel form of polyamide, which is being exploited to develop protein therapeutics with enhanced properties. Dr. Rose has been a consultant in the areas of protein chemistry and mass spectrom